BMS-Pfizer anti-coagulant Eliquis gets FDA nod

Singapore: US FDA has approved Bristol-Myers Squibb (BMS) and Pfizer's anticoagulant drug Eliquis (apixaban). The drug had previously been approved by the European Commission and the Japanese Ministry of Health, Labor and Welfare (MHLW). 

Eliquis is used for the prevention of venous thromboembolism and venous thromboembolic event. FDA approved the use of apixaban in December 2012 with an indication of reducing the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem. The drug was developed in a joint venture by Pfizer and Bristol-Myers Squibb.